ThromboGenics Appoints Emmanuele Attout as Independent

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ThromboGenics Appoints Emmanuele Attout as Independent Non-Executive Director

LEUVEN, Belgium, Jan. 22, 2015 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that its Board of Directors has nominated Emmanuèle Attout to be its new Independent non-executive director.  Mrs. Attout will join the Audit Committee of the Company.   

Mrs. Attout has been an audit partner at PricewaterhouseCoopers since 1994. She has been in charge of audits of a range of clients including banks, insurance companies, investment funds and assets managers.  She has in recent years been in charge of the audits of listed pharmaceuticals companies and life sciences business out of which she brings substantial relevant experience to the Board and to the Audit Committee.  

Dr Staf Van Reet, Chairman of ThromboGenics' Board of Directors, said: " We are delighted to welcome Emmanuèle to the ThromboGenics' board as a non-executive director. Her broad business and financial experience, will be extremely valuable to our Board and Audit Committee as we work to execute the standalone strategy we announced in mid-2014."
  
Commenting on her appointment, Mrs. Attout said: "I am very pleased to be joining the ThromboGenics Board. I have been impressed by the clear strategy that the Company has outlined to build a profitable business focused on providing innovative medicines for the treatment of a number of important vitreo-retinal diseases and I am looking forward to contributing to its successful execution."

END

For further information please contact:

 

ThromboGenics

 

Wouter Piepers,

Global Head of Corporate Communications & IR

+32 16 75 13 10 / +32 478 33 56 32

wouter.piepers@thrombogenics.com

 
 

Citigate Dewe Rogerson

 

David Dible/Malcolm Robertson

 

Tel: +44 20 7282 2867 

Malcolm.robertson@citigatedr.co.uk

 

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company's lead product, JETREA ® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. 

ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA ® outside the United States.

ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com .

About JETREA ® (ocriplasmin)

JETREA ® (ocriplasmin) is a truncated form of human plasmin. In the US, JETREA ® is indicated for the treatment of symptomatic VMA. In Europe, JETREA ® is indicated for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. JETREA ® is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play an important role in vitreomacular adhesion.

JETREA ® has been evaluated in two multi-center, randomized, double-masked Phase III trials conducted in the U.S. and Europe involving 652 patients with vitreomacular adhesion. Both studies met the primary endpoint of resolution of VMA at day 28.

JETREA's Phase III program found that 26.5% of patients treated with ocriplasmin saw resolution of VMA, compared with 10.1% of patients receiving placebo (p<0.01). The Phase III program also showed that JETREA was generally well tolerated with most adverse events being transient and mild in severity.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction.  No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

HUG#1888777

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Babe Ruth Lots Lead Morphy's $2 Million Collectibles Auction

Updated Category News Views 0

Ruth still pulls money like few names ever will, and Morphy's November 10-12 auction made that plain without any circus tricks. Three lots tied to the Yankees legend produced $136,500 within a Toys, Sports & General Collectibles sale that topped $2 million. That is not some vague nostalgia story. Buyers put real dollars behind a 1932 U.S. Caramel card, a 1933 Goudey card,...

Continue Reading
CMS Audit Proposal Reopens Medicare Advantage Risk

Updated Category News Views 104

A regulator just tossed a rusted anchor into managed care's earnings model. CMS's proposed Comprehensive Regulations to Uncover Suspicious Healthcare rule, dubbed CRUSH and numbered CMS-6098-P, puts Medicare Advantage risk-adjustment audits back at center stage. The headline nobody can casually wave away: audit findings from sampled enrollees could be extrapolated across...

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 138

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading
Cybersecurity's AI Tailwind Meets a Brutal Market Test

Updated Category News Views 89

Security software caught a bid while the rest of the tape was getting kicked down the stairs. That contrast is the whole story: investors saw Palo Alto Networks deliver a strong fiscal first quarter and raise its fiscal 2027 outlook, then decided cyber defense may be one of the few technology budgets companies cannot casually postpone. With AI helping attackers locate and...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 112

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
IAS Marks 42 Years Amid Germany Religious Freedom Win

Updated Category News Views 96

Bagpipes, country roads and a gathering from six continents made this far more than a routine anniversary reception. The International Association of Scientologists marked its 42nd anniversary at Saint Hill in East Grinstead, England, with thousands of Scientologists and guests arriving as autumn settled over West Sussex. That sort of turnout is a visible statement of...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 121

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 45

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
PTC Pushes Deeper Into Federal Product Development

Updated Category News Views 82

Federal engineering software is a miserable place to show up late, and PTC is plainly trying not to. Its November 19, 2026 expansion brings Windchill+ onto Microsoft Azure Government through PTC Cloud Services and introduces Onshape Government Federal for teams handling Controlled Unclassified Information. This is not a glamorous product refresh. It is a bid to remove the...

Continue Reading
A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 130

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading

Top 5 Most Recently Viewed Articles

Wesdome Gold Mines Pursues Significant Share Repurchase Plan

Updated Category News Views 220

Wesdome Gold Mines Initiates Share Buyback Program Wesdome Gold Mines Ltd. (TSX: WDO, OTCQX: WDOFF) is excited to unveil its plan for a Normal Course Issuer Bid (NCIB), which has just received approval from its board of directors and is pending final consent from the Toronto Stock Exchange (TSX). This strategic initiative allows the company to buy back a substantial 2% of...

Continue Reading
Zillow Faces August Class Action Deadline: Investor Alert

Updated Category News Views 51

Investor Tensions Rise Ahead of Zillow's Legal Deadline August 10, 2026—mark it down. That's your last call to jump into the fray with the class action suit against Zillow Group, Inc. (NASDAQ: ZG, Z), should you have skin in the game. We're talking investors who bought into Zillow from February 11, 2025, through May 7, 2026. Yeah, 'investor alert' might as well be...

Continue Reading
Explore Opportunities in the 2025 Global Omics Sciences Contest

Updated Category News Views 214

Unveiling the 2025 Mammoth International Contest on Omics Sciences Guided by esteemed organizations like UNESCO, the 2025 Mammoth International Contest on Omics Sciences offers young scientists an incredible platform to showcase their talents and innovative ideas. This initiative is proudly co-organized by BGI Research and the Jinze Charitable Foundation, unveiling a new...

Continue Reading
Navigating Disagreements: Jeff Bezos' Unique Leadership Style

Updated Category News Views 544

Embracing Different Perspectives: Jeff Bezos' Approach In a recent discussion, Jeff Bezos, the founder of Amazon.com, Inc. (NASDAQ: AMZN), reflected on his distinctive methodology for making decisions quickly and effectively. He believes that fostering an environment of trust and open dialogue is essential for overcoming disagreements. The Philosophy of Disagree and...

Continue Reading
Exploring Philanthropy's Impact on the U.S.-Mexico Border

Updated Category News Views 273

Unveiling Border Briefs in San Diego Recently, the U.S.-Mexico Border Philanthropy Partnership (BPP) introduced the Border Briefs series during an impactful event named Voices and Visions from the Border: A Funder Dialogue. This gathering was held at the San Diego Central Library, aiming to highlight the dynamic role that philanthropy plays in addressing challenges and...

Continue Reading